Oncolytic rhabdovirus
Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated oncolytic rhabdovirus encoding an M or G protein having an amino acid sequence at least 85% identical to SEQ ID NO:5 or SEQ ID NO:4.
2. The composition of claim 1 comprising an isolated recombinant oncolytic rhabdovirus encoding an M protein variant having an amino acid sequence at least 85% but less than 100% identical to SEQ ID NO:4.
3. The composition of claim 1 comprising an isolated recombinant oncolytic rhabdovirus encoding a G protein variant having an amino acid sequence at least 85% but less than 100% identical to SEQ ID NO:5.
4. The composition of claim 1 comprising an isolated recombinant oncolytic rhabdovirus encoding an M protein variant having an amino acid sequence at least 85% but less than 100% identical to SEQ ID NO:4 and encoding a G protein variant having an amino acid sequence at least 85% but less than 100% identical to SEQ ID NO:5.